Publications by authors named "Jason Brett"

Claim this Profile
T
The prevalence of cardiovascular disease by vascular bed and impact on healthcare costs in a large, real-world population with type 2 diabetes.
Wayne Weng, Sheldon X Kong, Rahul Ganguly, Malene Hersloev, Jason Brett

Endocrinol Diabetes Metab· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting.
Wayne Weng, Ye Tian, Sheldon X Kong, Rahul Ganguly, Malene Hersloev, Jason Brett

Clin Diabetes Endocrinol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
Wayne Weng, Ye Tian, Sheldon X Kong, Rahul Ganguly, Malene Hersloev, Jason Brett

Endocrinol Diabetes Metab· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials.
Patrick M O'Neil, Vanita R Aroda, Arne Astrup, Robert Kushner, David C W Lau, Jason Brett

Diabetes Obes Metab· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.
Maral DerSarkissian, Rachel H Bhak, Joanna Huang, Sarah Buchs, Francis Vekeman, Jason Brett

Curr Med Res Opin· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of liraglutide on endothelial function in patients with type 2 diabetes.
Debashis Nandy, Christopher Johnson, Rita Basu, Michael Joyner, Jason Brett

Diab Vasc Dis Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of biphasic insulin aspart 70/30 in type 2 diabetes patients of different race or ethnicity (INITIATEplus trial).
Bruce S Trippe, Mark D Shepherd, Franklin C Coulter, Anuj Bhargava, Jason Brett

Curr Med Res Opin· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program.
Robert R Henry, John B Buse, Giorgio Sesti, Melanie J Davies, Klaus H Jensen, Jason Brett

Endocr Pract· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.
Bruce W Bode, Jason Brett, Ali Falahati, Richard E Pratley

Am J Geriatr Pharmacother· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mild renal impairment and the efficacy and safety of liraglutide.
Jaime A Davidson, Jason Brett, Ali Falahati, David Scott

Endocr Pract· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
John B Buse, Alan Garber, Julio Rosenstock, Wolfgang E Schmidt, Jason H Brett

J Clin Endocrinol Metab· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes.
Stephen S Johnston, Christopher Conner, Mark Aagren, David M Smith, Jonathan Bouchard, Jason Brett

Diabetes Care· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIATEplus trial).
David S Oyer, Mark D Shepherd, Franklin C Coulter, Anuj Bhargava, Jason Brett

Am J Med· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett

Lancet· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis